Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
InspireMD, Inc. is a medical device company focused on the development and commercialization of technologies for the treatment and prevention of carotid artery disease and stroke. The company operates within the interventional cardiology and neurovascular segments of the broader medical devices industry. Its core product line centers on proprietary carotid stent systems designed to reduce embolic risk during and after carotid artery interventions.
The company’s primary revenue driver is its CGuard™ Embolic Prevention System, a carotid stent platform incorporating a micro-net covering intended to trap embolic debris and reduce the risk of stroke. InspireMD serves hospitals, interventional cardiologists, vascular surgeons, and neurointerventional specialists, with a strategic emphasis on differentiated clinical outcomes and safety. Founded in 2005, InspireMD originated as an Israel-based technology developer and later became publicly listed in the United States, evolving from early-stage R&D into a commercial-stage medical device company with expanding international reach.
Business Operations
InspireMD generates revenue through the sale of its CGuard™ family of carotid stent systems and related delivery technologies. The company operates primarily through a single-reportable operating segment focused on vascular medical devices, with research and development, regulatory, and manufacturing oversight centralized through its corporate structure. Commercial activities include direct sales and distributor-based models depending on region.
Operations span both domestic and international markets, with significant regulatory and commercial activity in Europe and other non-U.S. jurisdictions where carotid artery stenting adoption is more established. InspireMD controls proprietary stent design technology, including its MicroNet™ mesh architecture, and maintains manufacturing and supply-chain relationships with third-party partners. Data inconclusive based on available public sources regarding material joint ventures or equity-based strategic partnerships.
Strategic Position & Investments
The company’s strategic direction emphasizes clinical differentiation, regulatory expansion, and broader adoption of carotid stenting as an alternative to carotid endarterectomy. Key growth initiatives include expanding clinical evidence supporting CGuard™, pursuing additional regulatory approvals, and advancing next-generation iterations of its stent platforms.
InspireMD has historically invested heavily in clinical trials and post-market studies to support reimbursement and physician adoption, particularly in the United States. The company has not disclosed material acquisitions or a diversified investment portfolio, instead maintaining a focused strategy centered on internal product development and targeted commercialization. Data inconclusive based on available public sources regarding emerging technology investments outside carotid stenting.
Geographic Footprint
InspireMD is headquartered in the United States, with significant operational and research roots in Israel. The company maintains a strong commercial presence in Europe, where its flagship products have achieved earlier regulatory clearance and broader market penetration.
Beyond Europe and North America, InspireMD operates through distributors and commercial partners in select markets across Asia, Latin America, and other international regions. Its global footprint reflects a strategy of prioritizing regions with established carotid stenting reimbursement frameworks and experienced interventional physician bases.
Leadership & Governance
InspireMD was founded by Ran Margalit, who played a central role in the early development of the company’s carotid stent technology and strategic vision. The current leadership team is responsible for guiding the company through its clinical, regulatory, and commercial expansion phases. The leadership philosophy emphasizes evidence-based medicine, patient safety, and disciplined capital deployment.
Key executives include:
- Marcos Escaned, MD, PhD – President and Chief Executive Officer
- Data inconclusive based on available public sources – Chief Financial Officer
- Data inconclusive based on available public sources – Chief Operating Officer
The company is governed by a board of directors with experience in medical devices, capital markets, and healthcare innovation, providing oversight aligned with long-term shareholder value and regulatory compliance.